Considering TGF-β as a master pathogenic factor in DN, an important advantage of A2BAR antagonism lies in its ability to intervene in key signaling molecules downstream of TGF-β in podocytes, which are strongly linked to diabetic glomerulopathy. Here, TGFB1 is linked to liver dysplastic nodule.